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1. Introduction 
Radiotherapy (RT) can be effective for primary BCC, recurrent BCC or as adjuvant for 
incompletely excised BCC in patients where further surgery is neither possible nor 
appropriate. Radiotherapy is a mixture of superficial, electron beam, and brachytherapy for 
curved surfaces. Treatment in fractions over several visits may produce better cosmetic 
outcomes than a single fraction treatment.1 Radiotherapy is contraindicated in radiotherapy 
recurrent BCC, genetic syndromes predisposing to skin cancer and connective tissue 
disease. Significant side effects are radionecrosis, atrophy, and telangiectasia. Skin cancers 
can arise from radiotherapy field scars and should be avoided in younger age groups. 
Brachytherapy has been widely used for the treatment of head and neck cancers. Mold 
therapy is excellent for the treatment of superficial carcinomas because it allows the 
planning of an adequate dose distribution before treatment and provides highly 
reproducible irradiation.2,3 However, therapists and members of the nursing staff can be 
exposed to radiation if remote afterloading units are not used. Although the combination of 
mold and remote afterloading units has been used in the head and neck region, including 
the oral cavity,4-6 its use as a method of radical radiotherapy has been extremely limited 
because of the low flexibility of the connection catheters. Recently developed units with 192-
Ir microsources have more flexible catheters and molds that are better suited to uneven 
regions such as the oral cavity. The first case of superficial carcinoma of the nasal vestibule 
that was successfully treated by a technique combining a mold and a remote afterloading 
unit with a 192-Ir microsource was reported in 1992.7 However, no well-controlled case of 
treatment of an oral carcinoma through use of this combined technique has yet been 
reported, although trials of interstitial use are now in progress.8-11 Details on construction of 
molds used in this type of therapy have been described in the literature.12 Because of the 
favorable reports concerning the combined technique, we planned to use it for primary oral 
carcinomas as a part of radical radiotherapy. 
Basal cell carcinoma (BCC) is an epithelial tumor of the skin.13 It arises from the basal cells of 
the surface epidermis and can exhibit various clinical manifestations. It predominantly 
occurs on exposed areas of the skin. Actinic radiation is considered a major etiologic factor. 
It appears to be directly proportional to the amount of exposure of the skin to sunlight and 
is inversely proportional to the degree of skin pigmentation. Chronic arsenic exposure and 
genetic factors may also play a role in the development of BCCs. BCCs are highly variable 
and several different clinical types are recognized.13,14 
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Various methods have been used for treatment of BCC. These techniques have included 
electrocoagulation followed by curettage, electrosurgery, chemosurgery, chemotherapy, and 
radiation therapy.13,14 Radiation therapy can be delivered either by external beam radiation 
or by brachytherapy. Brachytherapy is usually applied in the form of interstitial therapy, 
which involves the implantation of radioactive sources into the tissues or the application of 
radioactive molds to the skin surface.15 Mold brachytherapy is usually delivered in specially 
constructed carriers. Surface radiation carriers primarily indicated for the treatment of 
superficial lesions. They are helpful where external radiation can be used as a boost dose.13 
Such carriers can vary in design from the simple to complex, according to treatment needs.14 
The radiation carrier should be easy to fabricate and be readily usable by the radiation 
oncologist. Carriers that will be worn for extended periods must be carefully constructed to 
provide maximal patient comfort and to ensure at the same time correct dose delivery to the 
treatment area and reproducibility of the treatment at repeated sessions. An irreversible 
hydrocolloid is used for making impression. The carrier can be constructed from 
autopolymerizing acrylic resin rather than heat-curing acrylic resin. Cerrobend alloy is 
chosen for shielding purposes.16 
2. Mold production procedure 
It consisted of a mold of polymethyl methacrylate (PMMA) of 5 mm thickness, built over a 
plaster mold obtained as an individual impression of the region of the face to be treated. The 
construction of this PMMA mold was very similar to the construction of dental prostheses. 
First, an impression of the region of the patient to be treated was obtained with 
condensation silicones of putty texture (Optosil, Bayer), carefully adapted to the surface of 
the skin with gentle pressure. Over this impression a plaster model was obtained, with the 
same surface characteristics as the patient’s face. Over this plaster model, the contours of the 
tumor were carefully drawn, requiring generally the presence of the patient. Over this 
plaster model, successive thin layers of acrylic material with catalyzer were deposited, until 
a minimum thickness of 5 mm was obtained, taking care to avoid sharp surfaces. This first 
layer of PMMA had to act as a bolus material and as a first support for the brachytherapy 
catheters. On it, the appropriate number of plastic tubes, covering the area to be treated, 
were fixed with an instant contact glue. Usually 3 to 7 parallel and equidistant tubes were 
placed, following the contour of the zone to treat, parallel to the skin’s surface and avoiding 
sharp turns. The distance between the catheters ranged between 5 to 10 mm. The next step 
was to check that the radioactive source ran without interruption along the entire length of 
the catheters, by connecting the tubes to the microselectron and running the check cable. In 
case of curvatures of a diameter smaller than that required to pass the microselectron source 
through the tube, the plastic tube was replaced and glued in a new position, checking again 
the pass of the source through the catheters. Only when the source passed through all 
channels without any problem, was the custom mold completed by adding the necessary 
quantity of PMMA acrylic material and catalyzer to cover all the catheters and to give 
solidity to the mold. To harden the assembly, it was heated to 70°C for 5 minutes with a hair 
dryer, taking care to avoid deformations of the guide tubes. In the sides of the applicator 
were built some, usually two, buttonholes in which an elastic tape was fixed to maintain the 
mold in the correct position during the entire treatment time and facilitating the reposition 
of the assembly for daily treatment. Treatment parameters were calculated by the 3D 
treatment planning software (Plato, Nucletron Int. BV). Each source dwell position was 
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weighted individually to ensure the best isodose distribution. Geometrical optimization in 
volume and distance was done. Isodoses at skin surface and at 5-mm depth were plotted 
and the dose to 5 easily identifiable dose points calculated. The treatment parameters were 
chosen, with the best fit of isodoses to the target volume. Before treatment, a test run 
without the patient was done: the mold was attached to the plaster model with 5 
thermoluminescent dosimeters (TLD) placed in the dose points and guide tubes connected 
to the microselectron. The results of the TLD were read and compared with the calculated 
values. A verification autoradiograph of the applicator was obtained modifying the 
prescribed dose to 50 cGy to the film but maintaining the same weight to each dwell time. In 
the cases of tumors close to the eye, a lead sheet 5 mm thick was placed in the corresponding 
zone of the mold in order to reduce the dose to the eye. The procedure of construction, 
dosimetry, and verification of the custom-made mold required 3 working days, requiring 2 
visits of the patient before beginning the treatment, one to take the impression of the face and 
the second to draw the tumor and treatment volume on the plaster model. The custom-made 
applicators were used to treat tumors of more than 2 cm diameter, or those of smaller size but 
seated in a non-flat region or a difficult-to-fix area with the Brock’s applicators. In one patient 
it was necessary to built a second mold at the halfway point of the treatment, due to changes in 
the surface of the skin resulting from tumor regression.  
2.1 Tolerance of custom-made molds 
All patients tolerated treatment without difficulties. Patients helped the nurses to fit the 
custom-made mold in place. Treatment time took 3 to 8 minutes in each session. The 
custom-made molds were very ease to use, and the patients felt comfortable during 
treatment. There were no cases of interruption of treatment resulting from break of the 
applicator or constriction of the plastic tubes preventing the radioactive source from 
traveling properly to the treatment dwell positions. 
2.2 Conclusions 
Radiotherapy is a highly effective treatment of skin carcinomas of the face and head. The 
use of HDR brachytherapy with custom-made external molds permits one to obtain a 
uniform dose distribution with a sharp gradient in the edges of the applicator. The custom-
made molds are easily used and permit a highly accurate daily treatment reproduction. 
They enable one to obtain excellent local control with minimum treatment-related sequelae 
or late complications. Given the excellent results, HDR brachytherapy with external custom-
made molds is a reasonable alternative to other radiation therapy techniques for the 
treatment of skin carcinomas of the head and face. 
3. Clinical reports 
3.1 Case report 1: A hinged flange radiation carrier for the scalp 
The purpose of this cases was to describe fabrication of a hinged flange radiation carrier for 
a patient with BCC of the scalp. 
A 63-year-old man with the chief complaint of scalp lesions of 15 years duration was 
examined at the Hacettepe University hospital. These lesions were biopsied and diagnosed 
www.intechopen.com
 
Basal Cell Carcinoma 4 
as BCC (Fig. 1). Radiation treatment of 4 days duration (details could not be obtained) to the 
scalp performed 45 years ago was noted in the patient’s history. Total scalp excision was 
suggested as the treatment of choice. However, the patient refused the surgical intervention 
because of cosmetic problems and was accordingly referred to the department of radiation 
oncology. The treatment that was selected was a specially constructed mold suitable for 
remotely controlled after-loading brachytherapy. The patient was referred to the 
department of prosthodontics for fabrication of the radiation carrier 
3.1.1 Procedure 
The catheter radiation carrier was fabricated to ensure the fixation of the after-loading 
catheters in the required orientation to make the treatment reproducible. For fractionated 
treatment, it was decided to fabricate a catheter carrier mold. The patient’s head was 
shaved, and the border of the shaved area was outlined on the skin with indelible pencil. 
The patient’s head was lubricated with petroleum jelly (Aafes). The moulage impression of 
his head was made with irreversible hydrocolloid impression material (Blueprint Cremix, 
Dentsply, DeTrey, England) supported with gypsum (Kristal Alçi Sanayi Ltd., Ankara, 
Turkey). The surface was outlined with a pencil and boxed with wax. The impression was 
then poured in dental stone. One layer of baseplate wax (1 mm in thickness) was adapted 
over the cast. The catheters were placed parallel to each other at spaces of 10 mm (Fig. 2). 
The spacing was determined by the radiation oncologist and the radiation physicist in 
accordance with dosimetry for the target volumes to avoid creating cold or hot spot areas in 
the treatment region. Autopolymerizing methyl methacrylate (Meliodent, Bayer Dental, 
Bayer UK Limited Bayer House, Newbury, U.K.) was prepared, poured, and spread over the 
surface. The device was designed to be two pieces from frontal to cervical border. An acrylic 
resin hinge was fabricated and embedded into the two pieces (Fig. 3, A and B). This 
approach was necessary because undercuts over the head prevented placement of the 
carrier as a single unit. After polymerization and trimming, the device was tried on the 
patient’s head and adjusted (Fig. 4). Remote control after-loading technique was used to 
provide radiation and to distribute the active sources in the mold. High dose rate (HDR) 
microselection equipment with Ir-192 source and 1.77 ´ 1011 Bq activity was used. A total 
dose of 4050 cGy at 0.5 cm skin depth was given over a period of 3 weeks. 
3.1.2 Discussion 
Radiation prostheses have assisted the delivery of radiotherapy for carcinomas. These 
prostheses are used to protect or displace vital structures from the radiation field, locate 
diseased tissues in a repeatable position during radiation treatment, position the radiation 
beam, carry radioactive material or dosimetric devices to the tumor site, recontour tissues to 
simplify the therapy, or shield tissues from radiation. Radiotherapy has been used in the 
management of the head and neck region for many years. It has been shown to be effective 
in the treatment of superficial lesions. 15,16 Superficial lesions usually have a higher cure rate 
with radiation than do deeply infiltrating lesions. Radiation treatment of BCC is reported to 
be 96.4% with radiation therapy.17 Small BCCs that occur in essential cosmetic area can be 
successfully treated with a short treatment course14 (Fig. 5). Surgery is indicated, especially 
when the lesions have arisen in damaged skin or have invaded cartilage.18 Modern 
brachytherapy is delivered by remote controlled after-loading systems where the 
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radioactive sources are delivered to the prepositioned treatment catheters HDR remote 
control after-loading brachytherapy is used in the treatment of patients with curative 
intent.19 There are several advantages in using HDR remotely controlled after-loading 
systems. Radiation exposure of treating and nursing staff is virtually eliminated. Patient 
immobilization time is short; therefore complications that result from prolonged bed rest, 
such as pulmonary emboli and patient discomfort, is decreased. Treatment planning and 
dosimetry are more exact. Radioactive sources can be accurately positioned to a specific 
region. The sources have been arranged for loading according to the results of calculations 
by the radiation physicist to determine dose distribution. This ensures delivery of the 
calculated degree of radiation. If a change in dosage is required, it can be adjusted 
accordingly. Treatment can be performed on an outpatient basis, reducing healthcare cost. 
The use of external carrier fixation devices allows more constant and reproducible geometry 
for source positioning. Surface radiation carriers are being used more frequently with high 
dose remote after-loading devices.19 
3.1.3 Conclusions 
A hinged flange cranial radiation carrier was fabricated for a patient with basal cell 
carcinoma of the scalp. This method allowed for accurate and repeatable positioning of the 
carrier to facilitate radiation therapy. The use of the after-loading principles of 
brachytherapy allowed for the delivery of an accurate dose of radiation while minimizing 
radiation exposure to the radiation oncologist and nursing staff. The patient is in complete 
remission 15 months after treatment. 
 
Fig. 1. View of patient with lesions on scalp. 
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Fig. 2. Catheters were embedded within wax plates and placed parallel to each other at 
intervals 10 mm on cast. 
 
 
A 
 
B 
Fig. 3. A, Outer view of carrier on cast. B, Inner view of carrier. 
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Fig. 4. Radiation carrier is placed and fixed on patient’s head. 
 
 
Fig. 5. View of patient’s scalp 15 months after radiation treatment. 
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3.2 Case report 2: Periauricular mold brachytherapy 
A 42-year-old male was referred to the Otorhinolaryngology Department of Hacettepe 
University with the clinical diagnosis of recurrent BCCA of the right pinna (Fig. 6). The 
patient was treated in 1992 for a lesion in the periauricular area that was totally excised and 
pathologically diagnosed as BCCA. In 1995, a recurrent BCCA lesion infiltrating into the 
parotid gland was excised; and in October 1995, a retroauricular recurrent BCCA was 
excised and the patient treated with electron beam radiotherapy at the dose of 5000 Gy 
using fraction size of 250 Gy in 1996. In October 1996, a recurrent BCCA in the fronto-
parietal area was excised; and in 2000, a recurrent BCCA in the remaining right auricle 
infiltrating to the mastoid process was excised. A recurrent tumor was then diagnosed in the 
mastoid cavity in September 2001 and a final attempt at excision of the tumor was made 
with known microscopic residual disease. It was then decided to treat the patient with 
brachytherapy. The patient was informed about possible severe side effects of the treatment, 
and the patient was referred to the Department of Prosthodontics for fabrication of a 
radiation carrier. The patient was reclined in dental chair; the head positioned allowing the 
patient to rest in a relaxed position with easy application of impression material to the lesion 
area. The neighboring area with hair was isolated with petroleum jelly, and the orifice of the 
outer auricular canal was filled with moist gauze. The external border of the area that was 
intended to be included in impression was outlined with utility wax (Moldwax; Sankay 
Ltd., Izmir, Turkey). An irreversible hydrocolloid impression material (Kromopan; Lascod 
Sp.H., Firenze, Italy) was mixed and poured over the target area and slightly pushed and 
directed to the desired areas with a brush. Then, a simple wrought wire metal mesh was 
applied over the impression material for eliminating possible distortions that may occur 
during the removal of the impression and subsequent setting of the cast. The impression 
was poured with a Type III dental stone (Amberok, Ankara, Turkey). A 0.5-mm thick layer 
of pink modeling wax plate (Multiwax; B.D.P Industry, Ankara, Turkey) was heated slightly 
and adapted onto the model to act as a spacer preventing the direct contact of catheters to 
the tissues, extending through the borders of the target area (Fig. 7). To avoid developing 
hot or cold spots, the spaces between the plastic carrier tubes (Nucletron; Veenendaal, 
Netherlands) and the space between tubes and tissues were standardized by the use of wax 
sheets of uniform thickness. The catheters were placed parallel to each other with 8 mm 
distance. As the surface of the target tissue was not perfectly smooth, the adaptation of 
catheters to the superficial contours of these areas was impossible; two catheters were 
superimposed in these areas where needed (Fig. 8). The mold was prepared with clear 
autopolymerizing acrylic resin (Akribel; Atlas- Enta, Izmir, Turkey) overextending 2 mm 
from the treatment area. The wax spacer was removed, and this area was filled with a soft-
lining material (Visco-Gel; Dentsply De Trey, Konstanz, Germany) to provide an excellent 
adaptation of the radiation mold to the target area (Figs. 9 and 10). A remote-controlled 
high-dose-rate (HDR) after-loading unit (microselectron; Nucletron) was used for the 
treatment. Q4The CTV defined as 5-mm tissue starting from the surface Q5 of the mold and 
therefore encompassing microscopically residual tumor volume. Dose calculations were 
performed using Plato brachytherapy treatment planning system (Nucletron). The dose was 
specified at the reference dose-rate curve encompassing the CTV. A total radiation dose 
prescribed to the reference isodose was 2500 cGy in 10 fractions in an overall treatment time 
of 5 days. The patient did well during and after the treatment. The patient was lost to 
followup, after followed in complete remission for 2 years. 
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3.2.1 Discussion 
Radiotherapy has been used in the adjunctive management of the head and neck region for 
many years. It has been shown to be effective in the treatment of superficial lesions 20,21. 
Superficial lesions usually have a higher cure rate with radiation than do deeply infiltrating 
lesions 20. Successful radiation treatment of BCCA is reported to be 96.4% with radiation 
therapy 28. Small BCCAs that ocur in critical cosmetic areas may be successfully treated with 
a short treatment course 21. Radiation delivery devices are important for delivery of 
radiotherapy and are used to protect or displace vital structures from the radiation field, 
locate diseased tissues in a repeatable position during succeeding radiation treatment 
sequences, position the radiation beam, carry radioactive material or dosimetric devices to 
the tumor site, recontour tissues to simplify the therapy, or shield tissues from radiation 20,21. 
However, the technique of implanting radioactive materials into target tissues may have 
potential disadvantages. The major concern is the potential for nonuniformity of the dose 
delivered throughout the implanted volume. This can occur if the radioactive sources are 
spaced too closely together (thereby producing a hot spot) or too far apart (leading to a cold 
spot). Therefore, brachytherapy (and particularly interstitial implantation therapy) requires 
the radiotherapist to have adequate technical and conceptual skills to achieve good radiation 
dose distribution 29. Some clinicians have stated that most patients who have had radiation 
treatment for malignancies will, in time, develop new cancers in the irradiated area. 
Experienced radiotherapists who carefully followed their patients for many years find this 
to be an extremely rare possibility and irradiation should never be withheld from the patient 
for this reason. The best local control results for patients with previously irradiated 
recurrent head and neck cancers were reported to be with brachytherapy 30. The reason for 
better local control was argued in the literature and reported that tumors with good 
prognostic factors (smaller tumors and oral cavity locations) were suitable for treatment 
with brachytherapy. Moreover, higher radiation dose could be delivered by brachytherapy 
30. Our patient was previously received high-dose external beam radiation, tumor and we 
decided to deliver reirradiation with brachytherapy. Q7 We delivered 25 Gy in 5 days, 
divided in 10 fractions. Most authors used similar fractionation; however, most used higher 
doses. Narayana et al. 31 also delivered HDR brachytherapy, a total dose of 34 Gy in 10 
fraction, twice daily, and reported 2-year local control rate of 71% for recurrent squamous 
cell carcinoma of the head and neck. Martinez-Monge et al. 32 also delivered HDR 
brachytherapy for previously irradiated recurrent head and neck carcinomas, the authors 
used 40 Gy in 10 fractions and achieved 4-year local control rate of 85.6%. We have only one 
case and unfortunately we could not report long-term followup. Because of basal carcinoma 
histopathology and prior external beam radiotherapy, we think that 25 Gy would be enough 
to achieve local control. There are many advantages of using HDR remotely controlled after-
loading radiation delivery systems that cannot be overlooked. This method takes advantage 
of the rapid decrease in dose with distance from a radiation source (inverse square law). The 
intensity of radiation is inversely proportional to the square of the distance from the source. 
Thus, a high radiation dose can be given to the tumor while sparing the surrounding normal 
tissues. Patient immobilization time is short; therefore, complications that result from 
prolonged bed rest, such as pulmonary emboli and patient discomfort, are decreased. 
Treatment planning and dosimetry are more exact. Radioactive sources can be accurately 
positioned to a specific region. The sources have been arranged for loading according to the 
results of calculations by the radiation physicist to determine dose distribution. This ensures 
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accurate delivery of the calculated magnitude of radiation. If a change in dosage is required, 
it can be adjusted accordingly. The use of external carrier fixation devices allows more 
constant and reproducible geometry for source positioning. Surface radiation carriers are 
being used more frequently with highdose remote after-loading devices 23. 
3.2.2 Conclusion 
This method allowed accurate and repeatable positioning of the radiation carrier to facilitate 
therapy. Carriers that will be worn for extended periods must be carefully constructed to 
provide maximal patient comfort and to ensure, at the same time, correct dose delivery to the 
treatment area and reproducibility of the treatment at repeated sessions. Mold brachytherapy 
is an option for reirradiation of recurrent head and neck tumors in selected group of patients. 
 
Fig. 6. Patient with recurrent basal cell carcinomas of right periauricular area. 
 
Fig. 7. Wax spacer and placement of catheters. 
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Fig. 8. Two catheters were superimposed in irregular areas. 
 
 
 
 
 
 
Fig. 9. Wax spacer removed and replaced with soft-lining material. 
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Fig. 10. Adaptation of brachytherapy appliance to target tissues. 
3.3 Case report 3: High dose rate mold brachytherapy of early gingival carcinoma 
The purpose of this clinical report is to present the use of mold brachytherapy in the 
management in gingival cancer.  
Gingival carcinomas are rare, constituting less than 2% of all head and neck tumors.33 
Surgery with intraoral resection of the tumor or wide excision with the underlying bony 
structures is the most preferred treatment approach.33 Radiation therapy is used as an 
adjunct to surgery and is the primary treatment modality in inoperable patients.33,34 
Radiotherapy can be applied either through external beam or by brachytherapy. However, 
mold brachytherapy is rarely used in the management of the head and neck tumors, it is a 
promising method with encouraging results.35 It has the advantages of low acute radiation 
morbidity and shortened treatment period compared with the external beam technique.  
3.3.1 Patient 1 
A 70-year-old edentulous woman was seen by her dentist with the complaint of ill-fitting 
dentures, which had been experienced for 2 months. A tumoral lesion that measured 25 × 15 
mm was detected in the left maxillary gingiva. A biopsy was performed on the lesion (Fig. 
11); histopathologic examination of the specimen was consistent with well-differentiated 
squamous cell carcinoma. She denied use of alcohol or tobacco, and it was learned that she 
had been wearing dentures for more than 30 years. The computerized tomography (CT) of 
the primary tumor and neck region showed no abnormality. The patient was staged as 
T2NOMO cancer of the maxillary gingiva and referred for primary radiation therapy. High 
dose rate (HDR) mold brachytherapy was applied, considering the size, site, stage and 
differentiation of the tumor, and age of the patient (Fig. 12). 
Brachytherapy was well tolerated without any acute side effects. Grade IV mucositis was 
observed immediately after the treatment and healed completely in 1 month. Complete 
regression of the tumor was observed 1 month after the treatment (Fig. 13). The patient is 
alive and disease-free 36 months after the treatment. 
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Fig. 11. Tumoral lesion at left side of maxillary gingiva before brachytherapy. 
 
 
Fig. 12. Application of mold brachytherapy. 
 
 
 
Fig. 13. Lesion from Figure 2, 1 month after brachytherapy, shows complete response. 
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3.3.2 Patient 2 
A 84-year-old edentulous woman with a 6-week history of an ill-fitting denture was 
admitted to the hospital at Hacettepe University. Physical examination revealed a tumoral 
mass that measured 30 × 15 mm on the maxillary left gingiva and leukoplakia on the 
neighboring mucosa. A biopsy specimen of the lesion disclosed moderately differentiated 
squamous cell carcinoma. There was no pathologic lymph node on physical examination 
and CT scan. The patient had a history of using dentures for the last 26 years and no history 
of alcohol or tobacco consumption. The patient was staged as T2NOMO carcinoma of the 
maxillary gingiva and referred to radiation therapy. Brachytherapy by customized dental 
mold was planned. No acute side effects were observed. However, grade III mucositis 
developed after the completion of treatment. Although complete resolution of tumor was 
achieved, the patient experienced dyspnea due to pleural effusion at the sixth month of 
follow-up. Her condition gradually deteriorated and she died of intercurrent disease with 
pleural metastases 6 months after the brachytherapy. 
3.3.3 Procedures 
3.3.3.1 Dental mold 
Irreversible hydrocolloid impressions of the maxillae were made for both patients and 
custom trays were fabricated onto the obtained cast. Final impressions were made with a 
medium viscosity additional cure silicone material (Coltene/Whaledent Inc, Mahwah, N.J.) 
and were poured in type III dental stone (Amberok, Ankara, Turkey). After trimming the 
post-dam area, 2 layers of modeling wax were heated and adapted onto the cast to obtain a 
uniform thickness denture base. The cast was then flasked, the elimination of wax was 
accomplished with hot water, and heat-cured acrylic resin (Meliodent Bayer, Newbury, 
Berkshire, U. K.) was used to process the stent. After deflasking and trimming away excess 
material, the tubes that would transport the radioactive source to the target site were placed 
into the resin base preserving approximately 10 mm distance between each other. Two 
plastic tubes of 6F diameter for the first patient (Fig. 14) and 4 tubes of the same types were 
used for the second patient (Fig. 15). Grooves were formed on the base to allow the tubes to 
closely contact the mucosa at the target site. The tubes were ending at the border of the 
target site and secured with clear autocuring acrylic resin. 
 
Fig. 14. Impression of maxillary gingiva and tumor using irreversible hydrocolloid paste 
(right) and acrylic resin dental mold with 2 6F plastic catheters incorporated within it, 
parallel to gingiva (left). 
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Fig. 15. Impression of maxillary gingiva and tumor of second patient (right) and acrylic resin 
dental mold with 4 6F plastic catheters incorporated (left). 
3.3.3.2 Brachytherapy 
Position of the dummy sources within the tubes were verified by simulation. Dosimetric 
calculations were performed by using the Plato Nucletron planning system (module BPS, 
Nucletron B.V., Veenendaal, The Netherlands). Irradiation was delivered by an Ir-192 HDR 
micro Selectron Afterloading unit. A total of 40 Gy was administered in 4 Gy fractions twice 
daily in 10 fractions and overall treatment time of 5 days for both patients. Special intraoral 
shielding lead blocks were used to shield buccal mucosa and tongue. Biologically equivalent 
doses for both patients were calculated to be 56 Gy10 for the tumor and 120 Gy2 for the late 
reacting tissues. Reference dose rate was 264.6 cGy/min and total air kerma was 0.06 cGy at 
1 m for the first patient and 162.7 cGy/min and 0.12 cGy at 1 m for the second patient. The 
active length of both sources were 2.5 cm and the dimensions of the specified reference dose 
volume was 3.5 × 2.5 × 1.5 cm for the first patient. Active length of the sources were 4.25 cm 
for 1 source and 4.75 cm for the remaining 2 sources of the second patient. The specified 
reference dose volume was 4 × 4.5 × 3.5 cm for the second patient.  
3.3.4 Discussion 
Gingival carcinomas are rare tumors and optimal treatment modality is not settled yet. Early 
lesions are mostly treated with surgery, the role of definitive radiotherapy in these cases is 
unclear. External beam radiotherapy is generally used postoperatively or rarely as a primary 
treatment in advanced lesions.33,34 Mold brachytherapy experience in oral cavity carcinomas 
is mostly with low dose rate brachytherapy.35-37 There are few reports in the literature on the 
use of HDR mold brachytherapy combined with or without external beam therapy and the 
optimal time; dose and fractionation for HDR brachytherapy has not yet been determined.38-
40 In 1 of these reports, an early carcinoma of the nasal vestibule was treated with HDR mold 
brachytherapy and treatment parameters of this patient were similar to our patients.7 After 
an extensive literature review, only 1 report was found on the use of dental molds with 
HDR remote brachytherapy.41 Eliminating the morbidity of surgery, preserving the function 
of major salivary glands, being an outpatient treatment procedure, and allowing simple 
repeated noninvasive treatments are the advantages of HDR mold brachytherapy. 
Inadequate previous experience is the major disadvantage of this technique. Although the 
follow-up period is relatively short, these patients seemed to indicate that HDR mold 
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brachytherapy alone may be used in the management of small volume cancers of the 
gingiva with satisfactory local control. It was presumed that brachytherapy may be used as 
a boost method after external beam radiation for larger lesions. Because there is not enough 
experience and data in oral cavity cancers of HDR brachytherapy, more patients should be 
treated to determine the optimal dose and fractionation. 
3.3.5 Summary 
Two elderly edentulous patients with the diagnosis of early stage cancer of the upper 
gingiva were treated by customized dental mold brachytherapy. Locoregional tumor control 
was achieved in both patients. One patient is alive without any evidence of disease 36 
months after treatment, the other patient died of distant metastasis shortly after 
brachytherapy. Brachytherapy, being easy to apply with short treatment time and good 
acute tolerance, is a good choice and effective modality for the management of early stage 
gingival cancer, particularly in elderly patients. 
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